Aldeyra Therapeutics' stock surged 11% as the FDA accepted its new drug application for dry eye disease treatment. The company's drug, reproxalap, shows promise in treating the condition.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing

Aldeyra Therapeutics' stock surged 11% as the FDA accepted its new drug application for dry eye disease treatment. The company's drug, reproxalap, shows promise in treating the condition.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing